Drugs Made In America Acquisition (DMIIR) Enterprise Value (2024 - 2025)

Drugs Made In America Acquisition (DMIIR) reported Enterprise Value of -$223.0 for Q4 2025, up 98.69% year-over-year from -$112.23 in Q4 2024, and up 99.93% on a QoQ basis from -$315087.0 in Q3 2025.

Drugs Made In America Acquisition (DMIIR) has 2 years of Enterprise Value data on file, last reported at -$223.0 in Q4 2025.

  • Quarterly Enterprise Value rose 98.69% year-over-year to -$223.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$223.0 (up 98.69% YoY) and the FY2025 annual result came in at -$223.0, up 98.69% from the prior year.
  • Enterprise Value grew to -$223.0 in Q4 2025 per DMIIR's latest filing, from -$315087.0 in the prior quarter.
  • Across five years, Enterprise Value topped out at -$223.0 in Q4 2025 and bottomed at -$315087.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Enterprise Value (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - -1.47 Mn
2 Berto Acquisition 316.66 Mn 316.66 Mn - -209,016.00
3 Centurion Acquisition 311.94 Mn 311.94 Mn - -28,828.00
4 Churchill Capital Corp IX 311.36 Mn 311.36 Mn - -167,798.00
5 Agriculture & Natural Solutions Acquisition 301.94 Mn 301.94 Mn - -1.00
6 Siddhi Acquisition Corp (Cayman Islands) 286.76 Mn 286.76 Mn - -456,983.00
7 Bold Eagle Acquisition 276.06 Mn 276.06 Mn - -521,352.00
8 Cartesian Growth Corp III 270.68 Mn 270.68 Mn - -
9 Oyster Enterprises II Acquisition 266.84 Mn 266.84 Mn - -691,167.00
10 Drugs Made In America Acquisition - - - -223.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -223.00
Sep 30, 2025 -315,087.00
Dec 31, 2024 -17,035.00